

Francesco Cicone

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9414198/publications.pdf>

Version: 2024-02-01

55
papers

1,365
citations

430874

18
h-index

361022

35
g-index

61
all docs

61
docs citations

61
times ranked

1863
citing authors

#	ARTICLE	IF	CITATIONS
1	Single-Fraction Versus Multifraction (3 Å– 9ÅGy) Stereotactic Radiosurgery for Large (>2Åcm) Brain Metastases: A Comparative Analysis of Local Control and Risk of Radiation-Induced Brain Necrosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1142-1148.	0.8	344
2	Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 103-111.	6.4	128
3	Dosimetry-based treatment planning for molecular radiotherapy: a summary of the 2017 report from the Internal Dosimetry Task Force. <i>EJNMMI Physics</i> , 2017, 4, 27.	2.7	71
4	EANM dosimetry committee recommendations for dosimetry of ¹⁷⁷ Lu-labelled somatostatin-receptor- and PSMA-targeting ligands. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 1778-1809.	6.4	70
5	Repeated stereotactic radiosurgery for patients with progressive brain metastases. <i>Journal of Neuro-Oncology</i> , 2016, 126, 91-97.	2.9	65
6	Variations in the practice of molecular radiotherapy and implementation of dosimetry: results from a European survey. <i>EJNMMI Physics</i> , 2017, 4, 28.	2.7	65
7	Volumetric assessment of recurrent or progressive gliomas: comparison between F-DOPA PET and perfusion-weighted MRI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 905-915.	6.4	58
8	Amino acid PET and MR perfusion imaging in brain tumours. <i>Clinical and Translational Imaging</i> , 2017, 5, 209-223.	2.1	54
9	Outcomes of postoperative stereotactic radiosurgery to the resection cavity versus stereotactic radiosurgery alone for melanoma brain metastases. <i>Journal of Neuro-Oncology</i> , 2017, 132, 455-462.	2.9	38
10	Advanced Imaging Techniques for Radiotherapy Planning of Gliomas. <i>Cancers</i> , 2021, 13, 1063.	3.7	31
11	Anatomical substrates of cognitive and clinical dimensions in first episode schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , 2012, 128, n/a-n/a.	4.5	28
12	Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?. <i>Current Urology Reports</i> , 2019, 20, 68.	2.2	27
13	Thyro-entero-gastric autoimmunity: Pathophysiology and implications for patient management. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2020, 34, 101373.	4.7	27
14	Long-term metabolic evolution of brain metastases with suspected radiation necrosis following stereotactic radiosurgery: longitudinal assessment by F-DOPA PET. <i>Neuro-Oncology</i> , 2021, 23, 1024-1034.	1.2	26
15	Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with ¹⁸ F-FDOPA PET. <i>British Journal of Radiology</i> , 2016, 89, 20160476.	2.2	25
16	First in-human radiation dosimetry of the gastrin-releasing peptide (GRP) receptor antagonist ⁶⁸ Ga-NODAGA-MJ9. <i>EJNMMI Research</i> , 2018, 8, 108.	2.5	25
17	¹⁸ F-DOPA uptake does not correlate with IDH mutation status and 1p/19q co-deletion in glioma. <i>Annals of Nuclear Medicine</i> , 2019, 33, 295-302.	2.2	25
18	First in-human radiation dosimetry of ⁶⁸ Ga-NODAGA-RGDyK. <i>EJNMMI Research</i> , 2017, 7, 43.	2.5	24

#	ARTICLE	IF	CITATIONS
19	¹⁸ F-DOPA uptake parameters in glioma: effects of patients' characteristics and prior treatment history. <i>British Journal of Radiology</i> , 2018, 91, 20170847.	2.2	18
20	Internal radiation dosimetry of a ¹⁵² Tb-labeled antibody in tumor-bearing mice. <i>EJNMMI Research</i> , 2019, 9, 53.	2.5	17
21	Prognostic value of FDG uptake by the bone marrow in squamous cell carcinoma of the head and neck. <i>Nuclear Medicine Communications</i> , 2008, 29, 431-435.	1.1	16
22	A theoretical dose-escalation study based on biological effective dose in radioimmunotherapy with ⁹⁰ Y-ibritumomab tiuxetan (Zevalin). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010, 37, 862-873.	6.4	16
23	Preclinical Evaluation and Dosimetry of [¹¹¹ In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1). <i>Molecular Imaging and Biology</i> , 2020, 22, 979-991.	2.6	15
24	A Monte Carlo model for the internal dosimetry of choroid plexuses in nuclear medicine procedures. <i>Physica Medica</i> , 2018, 49, 52-57.	0.7	14
25	Cardiac Radionuclide Imaging in Rodents: A Review of Methods, Results, and Factors at Play. <i>Frontiers in Medicine</i> , 2017, 4, 35.	2.6	13
26	The mean striatal ¹⁸ F-DOPA uptake is not a reliable cut-off threshold for biological tumour volume definition of glioma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1051-1053.	6.4	13
27	Monte Carlo ⁹⁰ Y PET/CT dosimetry of unexpected focal radiation-induced lung damage after hepatic radioembolisation. <i>Physics in Medicine and Biology</i> , 2020, 65, 235014.	3.0	10
28	Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after ⁹⁰ Y-ibritumomab tiuxetan. <i>Hematological Oncology</i> , 2011, 29, 131-138.	1.7	9
29	Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study. <i>Endocrine</i> , 2015, 49, 163-169.	2.3	8
30	Leptomeningeal disease and brain control after postoperative stereotactic radiosurgery with or without immunotherapy for resected brain metastases. , 2021, 9, e003730.		8
31	Quantification of Dose Nonuniformities by Voxel-Based Dosimetry in Patients Receiving ⁹⁰ Y-ibritumomab-Tiuxetan. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013, 28, 98-107.	1.0	7
32	Hyperhomocysteinemia in acute iatrogenic hypothyroidism: the relevance of thyroid autoimmunity. <i>Journal of Endocrinological Investigation</i> , 2018, 41, 831-837.	3.3	7
33	¹⁸ F-DOPA Positron Emission Tomography in Medulloblastoma: 2 Case Reports. <i>World Neurosurgery</i> , 2016, 93, 490.e7-490.e11.	1.3	6
34	Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma. <i>Brain Tumor Pathology</i> , 2017, 34, 179-181.	1.7	6
35	Metabolic Evolution of Brain Metastasis After Stereotactic Radiosurgery. <i>Clinical Nuclear Medicine</i> , 2020, 45, 557-558.	1.3	5
36	Dosimetry of nuclear medicine therapies: current controversies and impact on treatment optimization. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 65, .	0.7	5

#	ARTICLE	IF	CITATIONS
37	Radioimmunotherapy of heavily pre-treated, non-Hodgkin's lymphoma patients: efficacy and safety in a routine setting. <i>Anticancer Research</i> , 2009, 29, 4771-7.	1.1	5
38	Comparison of absorbed dose extrapolation methods for mouse-to-human translation of radiolabelled macromolecules. <i>EJNMMI Research</i> , 2022, 12, 21.	2.5	5
39	Three-Dimensional Patient-Specific Dosimetry in Radioimmunotherapy with ⁹⁰ Y-Ibritumomab-Tiuxetan. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2012, 27, 124-133.	1.0	4
40	Why not consider PET/CT in the workup of pulmonary tumour thrombotic microangiopathy?. <i>Journal of Cardiovascular Medicine</i> , 2015, 16, 73-74.	1.5	3
41	Dosimetric Approaches for Radioimmunotherapy of Non-Hodgkin Lymphoma in Myeloablative Setting. <i>Seminars in Nuclear Medicine</i> , 2022, 52, 191-214.	4.6	3
42	Tc-99m DTPA Cisternography Shows Disappearance of Cerebrospinal Fluid Leakage After Standing a Short Time. <i>Clinical Nuclear Medicine</i> , 2009, 34, 29-30.	1.3	2
43	Editorial: Nuclear Medicine in the Context of Personalized Medicine. <i>Frontiers in Medicine</i> , 2020, 7, 252.	2.6	2
44	Editorial: Perspectives in Small Animal Radionuclide Imaging. <i>Frontiers in Medicine</i> , 2020, 7, 262.	2.6	2
45	Reply to Zaragori et al.: ¹⁸ F-IDH mutation status associated with ¹⁸ F-FDopa PET uptake. <i>Annals of Nuclear Medicine</i> , 2020, 34, 230-231.	2.2	2
46	FET and FDOPA PET Imaging in Glioma. , 2020, , 211-221.		2
47	Not all that glitters is COVID! Differential diagnosis of FDG-avid interstitial lung disease in low-prevalence regions. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 19.	1.5	2
48	Fundamentals of internal radiation dosimetry. , 2022, , 607-621.		2
49	Repeated amino acid PET imaging for longitudinal monitoring of brain tumors. <i>Clinical and Translational Imaging</i> , 0, , .	2.1	1
50	Studying the Metabolic Activity of Red Bone Marrow by Means of FDG-PET: The Need for a Standardization. <i>Molecular Imaging and Biology</i> , 2008, 10, 129-130.	2.6	0
51	Comment on Hatzoglou et al: Dynamic contrast-enhanced MRI perfusion versus ¹⁸ F-FDG PET/CT in differentiating brain tumor progression from radiation injury. <i>Neuro-Oncology</i> , 2017, 19, now283.	1.2	0
52	In Reply to the Letter to the Editor Regarding ¹⁸ F-DOPA PET in Medulloblastoma: Two Case Reports. <i>World Neurosurgery</i> , 2021, 150, 255.	1.3	0
53	Reply to: ¹⁸ F-Assessment of imaging biomarkers in the follow-up of brain metastases after SRS. <i>Neuro-Oncology</i> , 2021, 23, 1985-1986.	1.2	0
54	Efficacy of Yttrium-90 Zevalin Outside of Clinical Trials: Preliminary Results of a Retrospective Bi-Center Study. <i>Blood</i> , 2008, 112, 5015-5015.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The Importance of Standardizing Acquisition Settings and Interpretation Criteria of Radionuclide Cisternography. Iranian Journal of Radiology, 2014, 11, e9057.	0.2	0